AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18471252 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic/docosahexaenoic PUFA supplements
Number of subjects: 30
Study 18471252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16509867 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 100
Study 16509867 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 100
Study 12668363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg/day
Number of subjects: 840
Study 12668363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 840
Study 10975513 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (60 mg/m2 per day for 7 days)
Number of subjects: 100
Study 10975513 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG/prednisone (15 mg/kg ATG bid plus 20 mg/m2 prednisone bid for 5 days, followed by an 8-week prednisone taper)
Number of subjects: 100
Study 10975513 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG/prednisone
Number of subjects: 100
Study 9172131 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sporadic ALS
Number of subjects: 11
Study 9172131 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control subjects
Number of subjects: 11
Study 8470851 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 400 micrograms two times daily during years 3 and 4
Number of subjects: 56
Study 8470851 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilator therapy (salbutamol, 400 micrograms, or ipratropium bromide, 40 micrograms) during the first 2 years
Number of subjects: 56
Study 3549971 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine
Number of subjects: 63
Study 3549971 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 63
Study 29777534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental treatment provided by a dentist four to five times a week, in addition to routine oral hygiene.
Number of subjects: 254
Study 29777534 — intervention group
Group type: COMPARATOR
Intervention: Routine oral hygiene including topical application of chlorhexidine provided by ICU nursing staff.
Number of subjects: 254
Study 29777534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental treatment
Number of subjects: 254
Study 26864095 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublebase Dayleve gel (DELP)
Number of subjects: 36
Study 25025057 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan rich oat bread
Number of subjects: 60
Study 25025057 — intervention group
Group type: COMPARATOR
Intervention: Wheat fiber bread (Control)
Number of subjects: 60
Study 22562609 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Number of subjects: 104
Study 22562609 — intervention group
Group type: EXPERIMENTAL
Intervention: CBR1 inhibition
Number of subjects: 104
Study 16040885 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12444180 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy
Number of subjects: 220
Study 12444180 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic esophagectomy with extended en bloc lymphadenectomy
Number of subjects: 220
Study 9696300 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 600 mg
Number of subjects: 12
Study 9696300 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400 mg
Number of subjects: 12
Study 9696300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 7650108 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 24
Study 7650108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee)
Number of subjects: 24
Study 2756353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg b.i.d. iv. for two days, followed by oral administration with 750 mg b.i.d. for a total of 14 days
Number of subjects: 36
Study 2756353 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline plus metronidazole according to a similar scheme of administration
Number of subjects: 36
Study 324570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic treatment
Number of subjects: 92
Study 324570 — intervention group
Group type: COMPARATOR
Intervention: Endocrine treatment
Number of subjects: 92
Study 324570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic treatment (premenopausal women)
Number of subjects: 92
Study 324570 — intervention group
Group type: COMPARATOR
Intervention: Endocrine treatment (ovarian ablation, premenopausal women)
Number of subjects: 92
Study 324570 — intervention group
Group type: COMPARATOR
Intervention: Endocrine treatment (tamoxifen, postmenopausal women)
Number of subjects: 92
Study 30760393 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy (mCIMT)
Number of subjects: 33
Study 30760393 — intervention group
Group type: COMPARATOR
Intervention: Bimanual Therapy (BIM)
Number of subjects: 33
Study 28003034 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise (PRE)
Number of subjects: 352
Study 28003034 — intervention group
Group type: COMPARATOR
Intervention: Compensatory Workplace Exercise (CWE)
Number of subjects: 352
Study 25910378 — intervention group
Group type: COMPARATOR
Intervention: LAC (lansoprazole 1 mg/kg/day, amoxicillin 50 mg/kg/day, clarithromycin 14 mg/kg/day for 14 days)
Number of subjects: 90
Study 25910378 — intervention group
Group type: EXPERIMENTAL
Intervention: LACE (LAC + vitamin E 200 IU/day for 14 days)
Number of subjects: 90
Study 22868073 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee arthroplasty
Number of subjects: 111
Study 22868073 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 111
Study 22868073 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal alignment within 3° of neutral
Number of subjects: 111
Study 22868073 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal alignment greater than 3°
Number of subjects: 111
Study 21122499 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-MMX(R) 9 mg tablets
Number of subjects: 36
Study 21122499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18765162 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (n=857)
Number of subjects: 1707
Study 18765162 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (n=850)
Number of subjects: 1707
Study 18765162 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent
Number of subjects: 1707
Study 18765162 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 1707
Study 16168062 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 12 microg twice daily
Number of subjects: 13
Study 16168062 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 10087413 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral methotrexate followed by 800 micrograms vaginal misoprostol 7 days later
Number of subjects: 310
Study 10087413 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral methotrexate followed by 800 micrograms vaginal misoprostol 7 days later
Number of subjects: 310
Study 10087413 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 310
Study 7587919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (administered 3 or 4 times a day)
Number of subjects: 22
Study 2215996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygrobac DAR 352 filter
Number of subjects: 0
Study 419422 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine intramuscularly
Number of subjects: 51
Study 419422 — intervention group
Group type: COMPARATOR
Intervention: No atropine (Control)
Number of subjects: 51
Study 31359814 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest algorithm
Number of subjects: 232
Study 31359814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge regression algorithm
Number of subjects: 232
Study 31138020 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 161
Study 31138020 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 161
Study 27771133 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for the Treatment of Emotional Disorders in Adolescents (UP‐A)
Number of subjects: 0
Study 27771133 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 0
Study 26319651 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour (IoL)
Number of subjects: 234
Study 26319651 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (EM)
Number of subjects: 234
Study 23292538 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% betamethasone valerate cream
Number of subjects: 47
Study 23292538 — intervention group
Group type: COMPARATOR
Intervention: 0.05% betamethasone valerate cream
Number of subjects: 47
Study 19256406 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement course at 6 months (RCG)
Number of subjects: 70
Study 19256406 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly phone contact (PHCG)
Number of subjects: 70
Study 19256406 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 70
Study 16500236 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 16500236 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Zometa) with Letrozole
Number of subjects: 0
Study 15022811 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient physiotherapy following total knee arthroplasty
Number of subjects: 120
Study 15022811 — intervention group
Group type: COMPARATOR
Intervention: No outpatient physiotherapy following total knee arthroplasty
Number of subjects: 120
Study 11220085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker patients with increased pacing rate
Number of subjects: 32
Study 11220085 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study 9571270 — intervention group
Group type: EXPERIMENTAL
Intervention: New spherical soft contact lenses
Number of subjects: 35
Study 9571270 — intervention group
Group type: COMPARATOR
Intervention: Spectacle correction
Number of subjects: 35
Study 8156285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine tablet (155 mg)
Number of subjects: 9
Study 29194749 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) 20 μg/d by subcutaneous injection
Number of subjects: 58
Study 29194749 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic Acid (ZOL) 5 mg/yr by intravenous infusion
Number of subjects: 58
Study 26928392 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin nightly for 5 nights
Number of subjects: 36
Study 26928392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25630243 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine-sulfate (1000 mg daily, for 8 weeks)
Number of subjects: 30
Study 25630243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23337343 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fat diet (diet M)
Number of subjects: 258
Study 23337343 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat diet (diet P)
Number of subjects: 258
Study 20848590 — intervention group
Group type: EXPERIMENTAL
Intervention: Automation-assisted screening
Number of subjects: 503391
Study 20848590 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytological screening
Number of subjects: 503391
Study 18828958 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40-120 mg/day)
Number of subjects: 0
Study 18828958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16773618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein products (LPP) diet
Number of subjects: 18
Study 16773618 — intervention group
Group type: COMPARATOR
Intervention: Balanced diet
Number of subjects: 18
Study 14618512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combinations of LABA and ICS
Number of subjects: 0
Study 14618512 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11054911 — intervention group
Group type: EXPERIMENTAL
Intervention: Possis AngioJet
Number of subjects: 0
Study 11054911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound thrombolysis device
Number of subjects: 0
Study 11054911 — intervention group
Group type: COMPARATOR
Intervention: Platelet IIb/IIIa inhibitors
Number of subjects: 0
Study 8882695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic saline (7 patients)
Number of subjects: 12
Study 8882695 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (5 patients)
Number of subjects: 12
Study 2051379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed partial dentures with periodontal therapy
Number of subjects: 0
Study 2051379 — intervention group
Group type: COMPARATOR
Intervention: Control (nonabutment) tooth
Number of subjects: 0
Study 6842024 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline intravenously
Number of subjects: 12
Study 6842024 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin plus aluminum monostearate (PAM) intramuscularly
Number of subjects: 12
Study 31004378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice containing 520 mg nitrate
Number of subjects: 15
Study 31004378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice containing 520 mg nitrate and 6 g citrulline
Number of subjects: 15
Study 31004378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice containing 520 mg nitrate and 6 g arginine
Number of subjects: 15
Study 31004378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15
Study 30086776 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB with 6ml 1% lidocaine
Number of subjects: 38
Study 30086776 — intervention group
Group type: COMPARATOR
Intervention: SGB with 6ml normal saline
Number of subjects: 38
Study 30086776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 38
Study 26661464 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF-MF exposure
Number of subjects: 50
Study 26661464 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-EMF exposure
Number of subjects: 50
Study 24253314 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1331
Study 24253314 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 1331
Study 24253314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function (measured by 3MS score)
Number of subjects: 1331
Study 24253314 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal memory
Number of subjects: 1331
Study 24253314 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal fluency
Number of subjects: 1331
Study 23155019 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal feeding (LIB)
Number of subjects: 360
Study 23155019 — intervention group
Group type: COMPARATOR
Intervention: Restricted feeding (R)
Number of subjects: 360
Study 23155019 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of fiber (3% inulin or 3% cellulose)
Number of subjects: 360
Study 23155019 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude protein content (14.5% vs 17.4%)
Number of subjects: 360
Study 19735336 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia Learning Education Program (MLEP)
Number of subjects: 54
Study 19735336 — intervention group
Group type: COMPARATOR
Intervention: Conventional Education Service Program (CESP)
Number of subjects: 54
Study 17687129 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with recombinant factor VIII
Number of subjects: 65
Study 17687129 — intervention group
Group type: COMPARATOR
Intervention: Enhanced episodic therapy
Number of subjects: 65
Study 16192764 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUAVAN Injection (AQ) at doses of 5, 10, 15, 20, 25, or 30 mg/kg
Number of subjects: 36
Study 16192764 — intervention group
Group type: COMPARATOR
Intervention: PropofolD (lipid emulsion) at equipotent doses
Number of subjects: 36
Study 16192764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AQ and PropofolD
Number of subjects: 36
Study 16192764 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ and PropofolGPI
Number of subjects: 36
Study 11277826 — intervention group
Group type: EXPERIMENTAL
Intervention: Gavestinel (800 mg loading dose + 200 mg every 12 hours for 3 days), n = 701
Number of subjects: 1367
Study 11277826 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 666
Number of subjects: 1367
Study 11277826 — intervention group
Group type: EXPERIMENTAL
Intervention: Gavestinel among patients receiving recombinant tissue‐type plasminogen activator, n = 333
Number of subjects: 1367
Study 11277826 — intervention group
Group type: EXPERIMENTAL
Intervention: Gavestinel and placebo overall
Number of subjects: 1367
Study 9678036 — intervention group
Group type: EXPERIMENTAL
Intervention: Gothenburg hip arthroplasty
Number of subjects: 0
Study 7741493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5 mg/kg
Number of subjects: 100
Study 7741493 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1.25 mg/kg
Number of subjects: 100
Study 7741493 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of Ketorolac and Pethidine
Number of subjects: 100
Study 2636483 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hydrogen peroxide mouth rinsing, 3 times daily for 3 weeks
Number of subjects: 0
Study 2636483 — intervention group
Group type: COMPARATOR
Intervention: 3% hydrogen peroxide pocket washing (clinical controlled)
Number of subjects: 0
Study 2636483 — intervention group
Group type: COMPARATOR
Intervention: 10% hydrogen peroxide Gingivox-strip, 3 times weekly for 3 weeks (clinical controlled)
Number of subjects: 0
Study 19138596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pingyangmycin sclerotherapy alone
Number of subjects: 79
Study 19138596 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with sclerotherapy
Number of subjects: 79
Study 19138596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pingyangmycin injection followed by histologic examination
Number of subjects: 79
Study 497075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl plus droperidol
Number of subjects: 0
Study 497075 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study 497075 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 0
Study 31989592 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training with Electromyostimulation (HIIT-EMS)
Number of subjects: 69
Study 31989592 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 69
Study 31989592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Recommendation from WHO
Number of subjects: 69
Study 31989592 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 69
Study 31272326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure reduction
Number of subjects: 1000
Study 31272326 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 1000
Study 28029656 — intervention group
Group type: EXPERIMENTAL
Intervention: Low lymphocyte-to-white blood cell ratio (LWR)
Number of subjects: 3243
Study 28029656 — intervention group
Group type: EXPERIMENTAL
Intervention: High monocyte-to-white blood cell ratio (MWR)
Number of subjects: 3243
Study 28029656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low LWR and high MWR
Number of subjects: 3243
Study 28029656 — intervention group
Group type: EXPERIMENTAL
Intervention: High neutrophil-to-white blood cell ratio (NWR)
Number of subjects: 3243
Study 28029656 — intervention group
Group type: EXPERIMENTAL
Intervention: High neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 3243
Study 28029656 — intervention group
Group type: EXPERIMENTAL
Intervention: High monocyte-to-lymphocyte ratio (MLR)
Number of subjects: 3243
Study 28029656 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet-to-lymphocyte ratio (PLR)
Number of subjects: 3243
Study 25631875 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) plus omeprazole and sucralfate
Number of subjects: 122
Study 25631875 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (omeprazole and sucralfate)
Number of subjects: 122
Study 24050519 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment initiated within 12 weeks of symptom onset
Number of subjects: 156
Study 24050519 — intervention group
Group type: COMPARATOR
Intervention: Private rheumatology practices
Number of subjects: 156
Study 24050519 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with morning stiffness
Number of subjects: 156
Study 24050519 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatologist-related delay
Number of subjects: 156
Study 24050519 — intervention group
Group type: EXPERIMENTAL
Intervention: Total delay from symptom onset until treatment initiation
Number of subjects: 156
Study 22523532 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (25% CR)
Number of subjects: 46
Study 22523532 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction plus exercise (CR+EX)
Number of subjects: 46
Study 22523532 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance diet (Control)
Number of subjects: 46
Study 19036082 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg daily plus pulsed dexamethasone 20 mg 4 days a month
Number of subjects: 103
Study 19036082 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha 3 MU 3 times a week plus pulsed dexamethasone 20 mg 4 days a month
Number of subjects: 103
Study 17380263 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free injection system (Intraject) with various device configurations
Number of subjects: 302
Study 17380263 — intervention group
Group type: EXPERIMENTAL
Intervention: Device gas mass (chamber pressure) and orifice size
Number of subjects: 302
Study 17380263 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) and injection site
Number of subjects: 302